KLRG1 is reduced on NK cells in SLE patients, inversely correlates with disease activity and is modulated by hydroxychloroquine in vitro

Objectives Killer cell lectin-like receptor G 1 (KLRG1), a transmembrane receptor with inhibitory capacity expressed in human immune cells, emerged as a novel susceptibility gene for systemic lupus erythematosus (SLE). The aim of this study was to investigate the expression of KLRG1 in SLE patients compared to healthy controls (HC) on both NK and T cells and to evaluate its possible involvement in SLE pathogenesis. Methods Eighteen SLE patients and twelve healthy controls were enrolled. Peripheral blood mononuclear cells (PBMCs) from these patients were phenotypically characterized by immunofluorescence and flow cytometry. The effect of the hydroxychloroquine (HCQ) in vitro on KLRG1 expression and its signaling mediated functions in NK cells were analyzed. Results KLRG1 expression was significantly reduced on the analyzed immune cell populations in SLE patients compared to HC, especially on total NK cells. Moreover, expression of KLRG1 on total NK cells inversely correlated with the SLEDAI-2K. A direct association between KLRG1 expression on NK cells and patients' treatment with HCQ was observed. In vitro treatment with HCQ increased KLRG1 expression on NK cells. In HC, KLRG1+ NK cells showed reduced degranulation and IFN gamma production, while in SLE patient, this inhibition occurred only for the IFN gamma production. Conclusion With this study we revealed a reduced expression and an impaired function of KLRG1 on NK cells in SLE patients. These results suggest a possible role of KLRG1 in the pathogenesis of SLE and as a novel biomarker of this disease.

Automated summary

This study investigated the expression of KLRG1 in SLE patients compared to healthy controls on both NK and T cells, as well as its possible involvement in SLE pathogenesis. The results showed that KLRG1 expression was significantly reduced on immune cell populations in SLE patients, especially on total NK cells. In addition, KLRG1 expression on NK cells was inversely correlated with disease activity and associated with treatment with HCQ. In vitro treatment with HCQ increased KLRG1 expression on NK cells. These findings suggest a role of KLRG1 in the pathogenesis of SLE and its potential as a biomarker for this disease.